SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-006876 to Ocean Biomedical, Inc. (OCEA, OCEAW) (CIK 0001869974) (OCEA)

Ocean Biomedical, Inc. (OCEA, OCEAW) (CIK 0001869974)
Date: June 28, 2023 · CIK: 0001869974 · Accession: 0000000000-23-006876

AI Filing Summary & Sentiment

File numbers found in text: 333-272859

Date
June 28, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Ocean Biomedical, Inc. (OCEA, OCEAW) (CIK 0001869974)

Letter

United States securities and exchange commission logo June 28, 2023 Elizabeth Ng Chief Executive Officer Ocean Biomedical, Inc. 55 Claverick St., Room 325 Providence , RI 02903 Re:Ocean Biomedical, Inc. Registration Statement on Form S-1 Filed June 22, 2023 File No. 333-272859 Dear Elizabeth Ng: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kate Bechen

Show Raw Text
United States securities and exchange commission logo
June 28, 2023
Elizabeth Ng
Chief Executive Officer
Ocean Biomedical, Inc.
55 Claverick St., Room 325
Providence , RI 02903
Re:Ocean Biomedical, Inc.
Registration Statement on Form S-1
Filed June 22, 2023
File No. 333-272859
Dear Elizabeth Ng:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kate Bechen